Paper Details

  1. Home
  2. Paper Details

A review of hydroxyurea-related cutaneous adverse events.

Author: DöhnerKonstanze, GriesshammerMartin, SadjadianParvis, StegelmannFrank, WilleKai

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Hydroxyurea (HU) is a common drug used to treat myeloproliferative neoplasms (MPN) and sickle cell disease (SCD). Although most patients tolerate HU well, cutaneous adverse events (CAE) are frequent and may limit its long-term use. In MPN patients, CAE are often underestimated and underdiagnosed. This review examines the available literature on HU-related CAE in MPN patients and emphasizes the importance of recognizing and managing these side effects.
Paper Details　
Original Abstract of the Article :
<b>Introduction</b>: Hydroxyurea (HU) is an S-phase specific oral chemotherapeutic agent that inhibits ribonucleotide diphosphate reductase. It is the most common used cytoreductive drug in patients (pts) with <i>BCR-ABL1</i> negative myeloproliferative neoplasms (MPN) and sickle cell disease (SCD)...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14740338.2021.1945032

データ提供：米国国立医学図書館（NLM）

Understanding Hydroxyurea-Related Cutaneous Adverse Events

This review focuses on [hydroxyurea (HU)]-related [cutaneous adverse events (CAEs)] in patients with [myeloproliferative neoplasms (MPN)]. The researchers discuss the frequency, impact, and management of these side effects, drawing upon data from both previously published studies and a recent prospective non-interventional study. The review highlights the need for careful monitoring and prompt intervention to minimize the impact of [HU]-related [CAEs].

Navigating the Challenges of Hydroxyurea Therapy

This review provides a valuable resource for clinicians managing patients with [MPN] who are treated with [HU]. The researchers offer practical recommendations for recognizing, preventing, and managing [HU]-related [CAEs], ensuring optimal patient care.

Improving Patient Safety and Quality of Life

This study emphasizes the importance of patient safety and quality of life in [HU] therapy. By raising awareness of [HU]-related [CAEs] and providing guidance for their management, the researchers aim to improve patient outcomes and minimize the impact of these side effects.

Dr.Camel's Conclusion

This review examines the [HU]-related [CAEs] that may accompany [MPN] treatment. Like a desert guide navigating the intricate paths of a vast landscape, this review provides essential information to guide clinicians in managing [HU] therapy and minimizing the risk of [CAEs].

Date :
  1. Date Completed 2021-12-03
  2. Date Revised 2021-12-14
Further Info :

Pubmed ID

34181494

DOI: Digital Object Identifier

10.1080/14740338.2021.1945032

Related Literature

Article Analysis
・Side Effects of hydroxyurea
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.